Abiopharma

New Form 6-K - Theratechnologies Inc. Filed: 2025-08-18 AccNo: 0001193125-25-182233 Size: 7 MB

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Bristol Myers Squibb - Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

iRhythm Technologies, Inc. - AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm’s Zio LTCM Clinical Superiority

Savara Inc. - Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025

AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm’s Zio LTCM Clinical Superiority

Alto Neuroscience, Inc. - Alto Neuroscience to Participate in Upcoming Investor Conferences

Alto Neuroscience to Participate in Upcoming Investor Conferences

New Form 8-K - ETHZilla Corp Filed: 2025-08-18 AccNo: 0001213900-25-077719 Size: 293 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 424B5 - NRX Pharmaceuticals, Inc. Filed: 2025-08-18 AccNo: 0001437749-25-027184 Size: 520 KB

The Oncology Institute and Doctors Healthcare Plans Partner to Elevate Oncology Care Management in South Florida

New Form 8-K - PRECIGEN, INC. Filed: 2025-08-18 AccNo: 0001104659-25-079497 Size: 4 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 8-K - STRATA Skin Sciences, Inc. Filed: 2025-08-18 AccNo: 0001140361-25-031629 Size: 9 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 8-K - Aptose Biosciences Inc. Filed: 2025-08-18 AccNo: 0001171843-25-005463 Size: 239 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 8-K - Adaptive Biotechnologies Corp Filed: 2025-08-18 AccNo: 0001193125-25-182222 Size: 133 KB Item 1.02: Termination of a Material Definitive Agreement